연구성과로 돌아가기

2023 연구성과 (164 / 285)

※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
WoS SCOPUS Document Type Document Title Abstract Authors Affiliation ResearcherID (WoS) AuthorsID (SCOPUS) Author Email(s) Journal Name JCR Abbreviation ISSN eISSN Volume Issue WoS Edition WoS Category JCR Year IF JCR (%) FWCI FWCI Update Date WoS Citation SCOPUS Citation Keywords (WoS) KeywordsPlus (WoS) Keywords (SCOPUS) KeywordsPlus (SCOPUS) Language Publication Stage Publication Year Publication Date DOI JCR Link DOI Link WOS Link SCOPUS Link
Article Synthesis and characterization of silica gel from Lapindo volcanic mud with ethanol as a cosolvent for desiccant applications Lapindo mud (LM) is a volcanic mud from a natural disaster that occurred 16 years ago in Sidoarjo District, East Java, Indonesia. The high amount of silica in the local materials of LM has been extracted for silica gel synthesis via hydrometallurgy methods, followed by sol-gel methods. The presence of ethanol in the synthesis process generated a unique textural property at different ratios between ethanol and sodium silicate (e/ss). Sol-gel mediated silica gel synthesis exhibited mesoporous properties with an amorphous structure, which is a characteristic of the silica gel. The silica gel exhibits silica nanoparticles over the average diameter of 2.08 nm with a spherical morphology and is connected to form an agglomeration structure. Increasing the e/ss ratio enhanced the amount of the hydroxyl group and the specific surface area ranged from 57 to 103 m(2) g(-1). The moisture adsorption performance of each silica gel showed that the silica gel with an e/ss ratio of 5 : 5 exhibited the highest adsorption capacity measured by conventional gravimetric methods and thermogravimetric analysis of 10.56% and 11.20% g(water) g(silica)(-1), respectively. These results indicated that the silica gel with an e/ss ratio has a high number of hydroxyl groups and more surface-active sites, which is beneficial for the adsorption process. The adsorption capacity of the synthesized silica gel is also higher than that of the commercial silica gel, indicating an excellent performance for desiccant applications. A'yuni, Qurrota; Rahmayanti, Ardhana; Hartati, Hartati; Purkan, Purkan; Subagyo, Riki; Rohmah, Nihayatur; Itsnaini, Luthfiyah Rifdah; Fitri, Medya Ayunda Univ Airlangga, Fac Sci & Technol, Dept Chem, Surabaya 60115, Indonesia; Univ Nahdlatul Ulama Sidoarjo, Dept Chem Engn, Fac Engn, Sidoarjo 61234, Indonesia; Univ Nahdlatul Ulama Sidoarjo, Fac Engn, Dept Environm Engn, Sidoarjo 61234, Indonesia; Inst Teknol Sepuluh Nopember, Fac Sci & Data Analyt, Dept Chem, Surabaya 60111, Indonesia; Kyungpook Natl Univ, Dept Wood & Paper Sci, Daegu 41566, South Korea; Univ Airlangga, Supra Modificat & Nanomicro Engn Res Grp, Surabaya 60115, Indonesia Subagyo, Riki/KSM-7820-2024; A'yuni, Qurrota/AAJ-2711-2021; Fitri, Medya/HJK-1405-2023; RAHMAYANTI, ARDHANA/GQP-4839-2022; Hartati, Hartati/AAM-5964-2021 57216337703; 57216333469; 59317174800; 37120862500; 57217120493; 58078807800; 58079814300; 57223101212 qrayuni@gmail.com; RSC ADVANCES RSC ADV 2046-2069 13 4 SCIE CHEMISTRY, MULTIDISCIPLINARY 2023 3.9 34.4 1.24 2025-06-25 10 12 SODIUM-SILICATE; HYDROXYL-GROUPS; ADSORPTION; NANOPARTICLES; CATALYST; EXTRACTION; KAOLINITE; MECHANISM; ERUPTION; WASTE Adsorption; Anatomy; Disasters; Ethanol; Gravimetry; Silicates; Sodium Compounds; Thermal Analysis; Adsorption; Disasters; Driers (materials); Ethanol; Morphology; Silica nanoparticles; Silicates; Sodium compounds; Sol-gel process; Sol-gels; Thermogravimetric analysis; Volcanoes; Cosolvents; Gel synthesis; Hydroxyl groups; Indonesia; Local materials; Natural disasters; Sodium silicate; Sol- gel methods; Synthesis and characterizations; Volcanics; Silica gel English 2023 2023-01-11 10.1039/d2ra07891k 바로가기 바로가기 바로가기 바로가기
Article Token-Level Fact Correction in Abstractive Summarization This paper addresses fact correction for abstractive summarization of which aim is to edit a system-generated summary into a new source-consistent summary. The summaries generated by abstractive summarization models often contain various kinds of factual errors. Thus, fact correction becomes essential to apply abstractive summarization to real-world applications. However, most existing methods for fact correction focus only on entity-level errors, which occasions the error correction methods to miss non-entity errors such as inconsistent tokens or mentions. Therefore, this paper presents a token-level fact correction that resolves inconsistencies of a system-generated summary at the token level. Since a token is the smallest meaning-bearing unit, all kinds of errors can be corrected if the errors are rectified at this level. The proposed fact corrector examines the consistency of a summary at the summary level like existing methods, but corrects the found inconsistencies at the token level. Thus, the proposed corrector consists of three modules of a summary fact checker, a token fact checker, and a fact emender. The summary fact checker inspects if a system-generated summary is factually consistent with a source text, the token fact checker finds out the tokens which cause inconsistency, and the fact emender actually replaces the inconsistency-causing tokens with correct tokens in the source text. Since these modules are closely related and affect one another, they are jointly trained to improve the performance of each module. The effectiveness of the proposed fact corrector is empirically proven from two viewpoints of consistency and summarization performance. For correcting inconsistencies in a summary, it is shown that the summaries by the proposed corrector are more factually consistent than those by its competitors. In addition, the proposed corrector outperforms the current state-of-the-art corrector even in automatic summarization performance. Shin, Jeongwan; Park, Seong-Bae; Song, Hyun-Je Kyungpook Natl Univ, Sch Comp Sci & Engn, Daegu 41566, South Korea; Kyung Hee Univ, Sch Comp Sci & Engn, Yonginsi 17104, Gyeonggido, South Korea; Jeonbuk Natl Univ, Dept Informat Technol & Engn, Jeonjusi 54896, Jeonrabugdo, South Korea 58086287500; 7501838676; 35175084000 hyunje.song@jbnu.ac.kr; IEEE ACCESS IEEE ACCESS 2169-3536 11 SCIE COMPUTER SCIENCE, INFORMATION SYSTEMS;ENGINEERING, ELECTRICAL & ELECTRONIC;TELECOMMUNICATIONS 2023 3.4 34.4 0.91 2025-06-25 6 7 Training data; Error correction; Abstracts; Measurement; Content analysis; Data models; Data mining; Text analysis; Token-level fact correction; factual consistency in abstractive summarization; summary fact checker; token fact checker; fact emender fact emender; factual consistency in abstractive summarization; summary fact checker; token fact checker; Token-level fact correction Abstracting; Data mining; Abstract; Content analysis; Errors correction; Fact emende; Factual consistency in abstractive summarization; Summary fact checker; Text analysis; Token fact checker; Token-level fact correction; Training data; Error correction English 2023 2023 10.1109/access.2022.3233854 바로가기 바로가기 바로가기 바로가기
Article Transfer Learning-Based Intrusion Detection System for a Controller Area Network The Controller Area Network (CAN) is a major protocol for in-vehicle network communications. This protocol is simple and efficient for message transmission and the smooth functioning of an in-vehicle system. On the other hand, the weaknesses of this protocol, such as the ID-based arbitration method for message transmission and lack of authentication mechanism, make it vulnerable to various security attacks, including DoS attacks, Fuzzy attacks, impersonation attacks, and replay attacks. Since there is no authentication mechanism for transmitted messages, we need a way to distinguish between normal and attack messages. An intrusion detection system (IDS) is an option for this problem because it can raise alarms when there are flaws in the system. IDS is very efficient for intrusion detection where messages with the same IDs are transmitted periodically. The deviation from the normal pattern of message transmission will force the IDS system to trigger alarms. Most studies on the CAN bus IDS system were based on a supervised learning approach. On the other hand, the lack of labeled datasets and a huge amount of training time make it inefficient for new attack patterns. This paper proposes a transfer learning-based IDS system for in-vehicle network intrusion detection. The extraction of quality features using transfer learning (TL) and appropriate fine-tuning methodology is used in the proposed model. This approach can use the available intrusion attack dataset to detect new attacks. The experimental results indicated that the proposed deep hybrid transfer learning (TL) model detects new threats with a high accuracy of approximately 99.9% when compared to state-of-the-art methods, while also lowering training and testing time by more than 30%. Khatri, Narayan; Lee, Sihyung; Nam, Seung Yeob Yeungnam Univ, Dept Informat & Commun Engn, Gyongsan 38541, South Korea; Kyungpook Natl Univ, Sch Comp Sci & Engn, Daegu 41566, South Korea Nam, Seung/Q-7486-2019; Khatri, Narayan/AAT-9029-2020 57222726965; 15623380100; 7402276352 synam@ynu.ac.kr; IEEE ACCESS IEEE ACCESS 2169-3536 11 SCIE COMPUTER SCIENCE, INFORMATION SYSTEMS;ENGINEERING, ELECTRICAL & ELECTRONIC;TELECOMMUNICATIONS 2023 3.4 34.4 1.68 2025-06-25 8 13 VANETs; intrusion detection system (IDS); transfer learning; supervised learning; security IN-VEHICLE; VEHICULAR NETWORKS; BLOCKCHAIN; LSTM intrusion detection system (IDS); security; supervised learning; transfer learning; VANETs Control system synthesis; Controllers; Deep learning; Denial-of-service attack; Internet protocols; Intrusion detection; Learning systems; Network security; Process control; Supervised learning; Vehicle to vehicle communications; Vehicle transmissions; Vehicular ad hoc networks; Authentication mechanisms; Controller-area network; In-vehicle networks; Intrusion detection system; Intrusion Detection Systems; Messages transmission; Security; Training time; Transfer learning; VANET; Authentication English 2023 2023 10.1109/access.2023.3328182 바로가기 바로가기 바로가기 바로가기
Article Two-Phase Evolutionary Convolutional Neural Network Architecture Search for Medical Image Classification Recently, convolutional neural networks (CNNs) have shown promising achievements in various computer vision tasks. However, designing a CNN model architecture necessitates a high-domain knowledge expert, which can be difficult for new researchers while solving real-world problems like medical image diagnosis. Neural architecture search (NAS) is an approach to reduce human intervention by automatically designing CNN architecture. This study proposes a two-phase evolutionary framework to design a suitable CNN model for medical image classification named TPEvo-CNN. The proposed framework mainly focuses on architectural depth search and hyper-parameter settings of the layered architecture for the CNN model. In the first phase, differential evolution (DE) is applied to determine the optimal number of layers for a CNN architecture, which enhances faster convergence to achieve CNN model architectures. In the second phase, the genetic algorithm (GA) is used to fine-tune the hyper-parameter settings of the generated CNN layer architecture in the first phase. Crossover and mutation operations of GA are devised to explore the hyper-parameter search space. Also, an elitism selection strategy is introduced to select the potential hyper-parameters of the CNN architecture for the next generation. The suggested approach is experimented on six medical image datasets, including pneumonia, skin cancer, and four COVID-19 datasets, which are categorized based on image types and class numbers. The experimental findings demonstrate the superiority of the proposed TPEvo-CNN model compared to existing hand-crafted, pre-trained, and NAS-based CNN models in terms of classification metrics, confusion matrix, radar plots, and statistical analysis. Ghosh, Arjun; Jana, Nanda Dulal; Das, Swagatam; Mallipeddi, Rammohan Natl Inst Technol Durgapur, Dept Comp Sci & Engn, Durgapur 713209, India; Indian Stat Inst, Elect & Commun Sci Unit, Kolkata 700108, India; Kyungpook Natl Univ, Dept Artificial Intelligence, Daegu 702701, South Korea Das, Swagatam/AAG-6753-2019; Mallipeddi, Rammohan/AAL-5306-2020 57219433879; 54795488300; 24729258600; 25639919900 mallipeddi.ram@gmail.com; IEEE ACCESS IEEE ACCESS 2169-3536 11 SCIE COMPUTER SCIENCE, INFORMATION SYSTEMS;ENGINEERING, ELECTRICAL & ELECTRONIC;TELECOMMUNICATIONS 2023 3.4 34.4 1.94 2025-06-25 12 15 Convolutional neural networks; Computer architecture; Computational modeling; Pulmonary diseases; Genetic algorithms; Differential equations; Neural engineering; Biomedical image processing; Convolutional neural network; differential evolution; genetic algorithm; medical imaging; neural architecture search DIFFERENTIAL EVOLUTION Convolutional neural network; differential evolution; genetic algorithm; medical imaging; neural architecture search Bioinformatics; Computer aided diagnosis; Computer architecture; Convolution; Differential equations; Genetic algorithms; Image classification; Medical problems; Network architecture; Neural networks; Pulmonary diseases; Computational modelling; Convolutional neural network; Differential Evolution; Hyper-parameter; Neural architecture search; Neural architectures; Neural engineering; Neural network architecture; Neural network model; Medical imaging English 2023 2023 10.1109/access.2023.3323705 바로가기 바로가기 바로가기 바로가기
Article A prospective, multicenter study on the clinical effectiveness of abiraterone in metastatic castration-resistant prostate cancer in Korea: Pre- vs. post-chemotherapy Purpose: The proper treatment sequence for administering abiraterone acetate plus prednisolone (AAP) and chemotherapeutic agents has not yet been elucidated for metastatic castration-resistant prostate cancer (mCRPC). Hence, this study evaluated the effectiveness and safety of AAP in pre-and post-chemotherapy settings using real-world data.Materials and Methods: This prospective, multicenter, open-label, observational study included 506 patients with mCRPC. Patients were classified according to the timing of chemotherapy into pre-and post-chemotherapy groups. The effectiveness and safety of AAP were compared between the groups; the prostate-specific antigen (PSA) response, PSA progression-free survival, and radiologic progression-free survival were assessed; and adverse drug reactions were recorded.Results: Among the included patients, 319 and 187 belonged to the pre-and post-chemotherapy groups, respectively. Risk classification was similar between the two groups. The PSA response was 61.8% in the pre-chemotherapy group and 39.0% in the post chemotherapy group (p<0.001). The median time to PSA progression (5.00 vs. 2.93 mo, p=0.001) and radiologic progression-free survival (11.84 vs. 9.17 mo, p=0.002) were significantly longer in the pre-chemotherapy group. Chemotherapy status was associated with PSA (hazard ratio [HR] 1.39, 95% confidence interval [CI] 1.09-1.77) and radiologic progression (HR 1.66, 95% CI 1.18-2.33) during AAP treatment. Adverse drug reactions were reported at similar frequencies in both groups.Conclusions: In this postmarketing surveillance, AAP benefited patients with mCRPC, especially in settings before chemotherapy was administered, resulting in a high PSA response and longer PSA and radiologic progression-free survival with tolerable adverse drug reactions. Jeong, Seung-hwan; Yeon, Sang Eun; Kim, Su Youn; Kwon, Tae Gyun; Jeon, Seong Soo; Choi, Young Deuk; Kwon, Dongdeuk; Ha Chung, Byung; Hong, Sung-Hoo; Kim, Byung Hoon; Lee, Hyo Jin; Shin, Sang Joon; Choi, Woo Suk; Park, Sung Woo; Kang, Taek Won; Yun, Seok Joong; Cho, Jin Seon; Choi, See Min; Lee, Na-Ri; Kwak, Cheol Seoul Natl Univ Hosp, Dept Urol, 101 Daehak Ro, Seoul 03080, South Korea; Janssen Korea Ltd, Med Affairs, Seoul, South Korea; Yonsei Univ, Coll Med, Dept Biostat & Comp, Seoul, South Korea; Kyungpook Natl Univ, Sch Med, Dept Urol, Daegu, South Korea; Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Urol, Seoul, South Korea; Yonsei Univ, Yonsei Univ Hlth Syst, Dept Pediat, Coll Med, Seoul, South Korea; Chonnam Natl Univ, Hwasun Hosp, Dept Urol, Hwasun, South Korea; Yonsei Univ, Coll Med, Gangnam Severance Hosp, Dept Urol, Seoul, South Korea; Catholic Univ Korea, Seoul St Marys Hosp, Dept Urol, Seoul St, Seoul, South Korea; Keimyung Univ, Sch Med, Dongsan Hosp, Dept Urol, Daegu, South Korea; Chungnam Natl Univ, Canc Res Inst, Coll Med, Infect Control Convergence Res Ctr, Daejeon, South Korea; Yonsei Univ, Yonsei Canc Ctr, Dept Internal Med, Div Med Oncol,Coll Med, Seoul, South Korea; Konkuk Univ, Med Ctr, Dept Urol, Sch Med, Seoul, South Korea; Pusan Natl Univ, Yangsan Hosp, Dept Urol, Yangsan, South Korea; Chonnam Natl Univ, Chonnam Natl Univ Hosp, Dept Urol, Med Sch, Gwangju, South Korea; Chungbuk Natl Univ, Coll Med, Chungbuk Natl Univ Hosp, Dept Urol, Cheongju, South Korea; Hallym Univ, Coll Med, Dept Urol, Anyang, South Korea; Gyeongsang Natl Univ, Sch Med, Gyeongsang Natl Univ Hosp, Dept Urol, Jinju, South Korea; Jeonbuk Natl Univ, Med Sch, Dept Internal Med, Jeonju, South Korea Cho, Young-Seok/J-5670-2012; Choi, See/G-8227-2014; Kwak, Cheol/J-2731-2012; Kim, Byung-Hoon/AFB-5417-2022; park, sung woo/JTS-5921-2023; Choi, See Min/G-8227-2014 57205703395; 57366967800; 57218685477; 15073765400; 7203005276; 7404777694; 7103159860; 56401513800; 37030299600; 57203500751; 57357625700; 57967744400; 57220979497; 57185889000; 36065936000; 16302421300; 35241941000; 9733562400; 15623367100; 7005639032 mdrafael@snu.ac.kr; INVESTIGATIVE AND CLINICAL UROLOGY INVESTIG CLIN UROL 2466-0493 2466-054X 64 5 SCIE UROLOGY & NEPHROLOGY 2023 2.5 34.5 0 2025-06-25 0 0 Abiraterone; Prostate cancer; Prostate-specific antigen; Real-world data SURVIVAL ANALYSIS; DOUBLE-BLIND; ACETATE Abiraterone; Prostate cancer; Prostate-specific antigen; Real-world data Drug-Related Side Effects and Adverse Reactions; Humans; Male; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Republic of Korea; Treatment Outcome; abiraterone; alanine aminotransferase; aspartate aminotransferase; C reactive protein; cyclophosphamide; prednisolone; prostate specific antigen; abiraterone; adult; adverse drug reaction; aged; Article; cancer chemotherapy; clinical effectiveness; confidence interval; confusion; diabetes mellitus; disease duration; drug efficacy; drug safety; fatigue; female; fever; hazard ratio; human; hypertension; hypokalemia; major clinical study; male; metastatic castration resistant prostate cancer; mild hepatic impairment; multicenter study; observational study; open study; overall survival; peripheral edema; postmarketing surveillance; progression free survival; prospective study; thrombocytopenia; adverse drug reaction; castration resistant prostate cancer; clinical trial; prospective study; South Korea; treatment outcome English 2023 2023-09 10.4111/icu.20230128 바로가기 바로가기 바로가기 바로가기
Article Clinical characteristics of surgically managed patients with asymptomatic renal stones : Comparison of patients with symptomatic renal stones Purpose: This study aimed to compare the characteristics of asymptomatic and symptomatic nephrolithiasis in patients who underwent surgical treatment for kidney stones. Materials and Methods: Between 2015 and 2019, 245 patients who underwent percutaneous nephrolithotomy or retrograde intrarenal surgery for kidney stones were included. The patients were divided into asymptomatic (n=124) and symptomatic (n=121) groups. All patients underwent blood and urine tests, preoperative non-contrast computed tomography, and postoperative stone composition analysis. We retrospectively analyzed and compared the characteristics of the patients and stones, operation time, stone-free rate, and postoperative complications between the two groups. Results: In the asymptomatic group, mean body mass index (BMI) was significantly higher (25.7 +/- 3.8 kg/m(2) vs. 24.3 +/- 2.8 kg/m(2), p=0.002) and urine pH was significantly lower (5.6 +/- 0.9 vs. 5.9 +/- 0.9, p=0.013). The ratio of calcium oxalate dihydrate stones was significantly higher in the symptomatic group (5.3% vs. 15.5%, p=0.023). No significant differences were observed in stone characteristics, postoperative outcomes, or complications. In the multivariate logistic regression analysis for predicting variables for asymptomatic renal stones, BMI (odds ratio [OR], 1.144; 95% confidence interval [CI], 1.038-1.260; p=0.007), and urine pH (OR, 0.608; 95% CI, 0.407-0.910; p=0.016) were independent predictive variables for asymptomatic renal stones. Conclusions: This study demonstrated that thorough medical check-ups are needed for the early detection of renal stones in indi-viduals with a high BMI or low urine pH. Park, Dong Jin; Kim, Bum Soo; Kwon, Soon Oh; Chung, Jae-Wook; Ha, Yun-Sok; Choi, Seock Hwan; Kim, Hyun Tae; Yoo, Eun Sang Dongguk Univ, Dept Urol, Coll Med, Gyeongju, South Korea; Kyungpook Natl Univ Hosp, Dept Urol, Sch Med, Daegu, South Korea; Kyungpook Natl Univ Hosp, Dept Urol, Daegu, South Korea; Uro United Urol Clin, Daegu, South Korea; Kyungpook Natl Univ, Chilgok Hosp, Dept Urol, Daegu, South Korea; Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Sch Med, Dept Urol, 680 Gukchaebosang Ro, Daegu 41944, South Korea ; Kim, Soo-Yeon/ADR-9663-2022 57220636322; 57202817150; 58133138000; 35204798500; 35487226400; 9742645500; 55739531300; 7006609239 uroyoo@knu.ac.kr; INVESTIGATIVE AND CLINICAL UROLOGY INVESTIG CLIN UROL 2466-0493 2466-054X 64 2 SCIE UROLOGY & NEPHROLOGY 2023 2.5 34.5 1.13 2025-06-25 4 4 Asymptomatic diseases; Body mass index; Kidney calculi NEPHROLITHIASIS; UROLITHIASIS; ASSOCIATION; PREVALENCE; PREDICTION; WEIGHT; BURDEN; COHORT Asymptomatic diseases; Body mass index; Kidney calculi Body Mass Index; Humans; Kidney Calculi; Nephrolithotomy, Percutaneous; Operative Time; Retrospective Studies; calcium oxalate; adult; Article; blood sampling; body mass; comparative study; computer assisted tomography; echography; female; follow up; hospitalization; human; major clinical study; male; nephrolithiasis; operation duration; percutaneous nephrolithotomy; postoperative complication; preoperative evaluation; propensity score; receiver operating characteristic; retrospective study; sensitivity and specificity; stone analysis; urea nitrogen blood level; urinalysis; urine pH; adverse event; diagnostic imaging; nephrolithiasis; percutaneous nephrolithotomy English 2023 2023-03 10.4111/icu.20220271 바로가기 바로가기 바로가기 바로가기
Article Development of irrigation schedule and management model for sustaining optimal crop production under agricultural drought Agriculture is vulnerable to drought indicating that the increasing climate crisis requires the necessity of sustainable crop production. In this study, we developed the Irrigation Schedule and Management (ISM) model based on a simulation-optimization (Soil Water Atmosphere Plant-SWAP model with Genetic Algorithm-GA) framework. The ISM model finds an optimal combination of Irrigation Water Amount (IWA) and Irrigation Interval (II) by adjusting Water Stress (WS) responding to environmental conditions (weather, soils, crops and bottom boundary conditions) throughout growing periods. By conditioning the crop (WS) and water management (IWA and II) variables, ISM improves the sustainability of optimal crop productions under different climatic-land surface conditions. The Regional Agromet Center (RAC) site in Faisalabad (at Punjab, Pakistan) was selected to test the proposed ISM model for the field validation/synthetic numerical experiments with various crops (Wheat, Corn and Potato) and soils. We demonstrated that the ISM model that reflects the relationship between crop and water management variables improved the sustainability of crop productions and Water Productivity (WP) compared to those of the conventional irrigation method at the RAC site under various environment conditions. Additionally, the ISM-based long-term crop productions showed the variations along the yearly precipitation changes indicating that optimal combinations of the crop and water management variables are considerably influenced by environmental conditions. Although uncertainties exist, our proposed ISM model can contribute to the establishment of efficient irrigation schedule/management plans under agricultural drought. Lee, Taehwa; Jang, Won Seok; Chun, Beomseok; Ahmad, Mirza Junaid; Jung, Younghun; Kim, Jonggun; Shin, Yongchul Kyungpook Natl Univ, Dept Agr Civil Engn, 80 Daehak Ro, Daegu 41566, South Korea; Kangwon Natl Univ, Dept Ecol Landscape Architecture Design, Kangwondaehak Gil 1, Chuncheon Si 24341, South Korea; Kyungpook Natl Univ, Dept Construct & Disaster Prevent Engn, 2559 Gyeongsang Daero, Sangju Si 37224, Gyeongsangbuk D, South Korea; Kangwon Natl Univ, Coll Agr & Life Sci, Dept Reg Infrastruct Engn, 1 Gangwondaehakgil, Chuncheon Si 24341, Gangwon Do, South Korea Ahmad, Mirza/AAD-5982-2020 57923692800; 35435352400; 57924798900; 57201479907; 55195880200; 35435507500; 55659438100 ycshin@knu.ac.kr; PADDY AND WATER ENVIRONMENT PADDY WATER ENVIRON 1611-2490 1611-2504 21 1 SCIE AGRICULTURAL ENGINEERING;AGRONOMY 2023 1.9 34.5 1.44 2025-06-25 9 10 ISM; Irrigation water amount; Irrigation interval; Water stress; Optimal crop production; Water productivity WATER-USE EFFICIENCY; CLIMATE-CHANGE; SOIL-MOISTURE; HYDRAULIC CONDUCTIVITY; YIELD; ALGORITHM; BALANCE; SYSTEM; WHEAT Irrigation interval; Irrigation water amount; ISM; Optimal crop production; Water productivity; Water stress Faisalabad; Pakistan; Punjab [Pakistan]; Crops; Cultivation; Drought; Genetic algorithms; Irrigation; Productivity; Soil moisture; Sustainable development; Crop production; Irrigation interval; Irrigation management; Irrigation schedule; Irrigation water amount; Irrigation waters; Optimal crop production; Water amount; Water productivity; Water stress; agricultural management; agricultural soil; climate change; climate conditions; crop plant; crop production; drought; environmental conditions; irrigation system; precipitation (climatology); sustainability; sustainable development; water management; water stress; Water management English 2023 2023-01 10.1007/s10333-022-00911-9 바로가기 바로가기 바로가기 바로가기
Article Korean Society of Endourology and Robotics (KSER) recommendation on the diagnosis, treatment, and prevention of urolithiasis This article provides evidence-based recommendations and expert opinions to aid urologists in making optimal decisions regarding managing urolithiasis in various clinical scenarios. The most frequently asked questions by urologists in their clinical practice have been collected and answered in the form of FAQs; based on the latest evidence and expert opinions. The natural history of urolithia-sis is divided into active treatment and silent phases, with the active treatment stage divided into typical and special situations and peri-treatment management. The authors address 28 key questions, offering practical guidance for the proper diagnosis, treatment, and prevention of urolithiasis in clinical practice. This article is expected to be served as a valuable resource for urologists. Jung, Do Hae; Lee, Joo Yong; Kang, Dong Hyuk; Ko, Kyungtae; Koh, Dong Hoon; Kwon, Ohseong; Koo, Kyo Chul; Kim, Kwang Taek; Kim, Myung Soo; Kim, Bum Soo; Kim, Hyeon Woo; Park, Juhyun; Bang, Woojin; Oh, Kyung-Jin; Yoon, Young Eun; Lee, Ki Soo; Lee, Dong Sup; Lee, Sang Hyub; Lee, Seungsoo; Lee, Hun Joo; Jung, Wonho; Cho, Dae Sung; Cho, Sung Yong; Choo, Min Soo; Choi, Jae Young; Choi, Taesoo; Han, Deok Hyun; Han, Byoung Kyu; Jeon, Seung Hyun; Paick, Sunghyun; Seo, Ill Young; Kim, Hyung Joon Inje Univ, Ilsan Paik Hosp, Coll Med, Dept Urol, Goyang, South Korea; Yonsei Univ, Severance Hosp, Coll Med, Urol Sci Inst,Dept Urol, Seoul, South Korea; Yonsei Univ, Inst Convergence Sci, Ctr Evidence Based Med, Seoul, South Korea; Inha Univ, Coll Med, Dept Urol, Incheon, South Korea; Hallym Univ, Kangdong Sacred Heart Hosp, Coll Med, Dept Urol, Seoul, South Korea; Konyang Univ, Coll Med, Dept Urol, Daejeon, South Korea; Hallym Univ, Kangnam Sacred Heart Hosp, Coll Med, Dept Urol, Seoul, South Korea; Yonsei Univ, Gangnam Severance Hosp, Coll Med, Dept Urol, Seoul, South Korea; Gachon Univ, Gil Med Ctr, Coll Med, Dept Urol, Incheon, South Korea; Ewha Womans Univ, Coll Med, Dept Urol, Seoul, South Korea; Kyungpook Natl Univ, Sch Med, Dept Urol, Daegu, South Korea; Pusan Natl Univ, Pusan Natl Univ Hosp, Sch Med, Dept Urol, Busan, South Korea; Univ Ulsan, Asan Med Ctr, Coll Med, Dept Urol, Seoul, South Korea; Hallym Univ, Hallym Sacred Heart Hosp, Coll Med, Dept Urol, Anyang, South Korea; Chonnam Natl Univ, Chonnam Natl Univ Hosp, Med Sch, Dept Urol, Gwangju, South Korea; Hanyang Univ, Coll Med, Dept Urol, Seoul, South Korea; Dong A Univ, Coll Med, Dept Urol, Busan, South Korea; Catholic Univ Korea, St Vincents Hosp, Coll Med, Dept Urol, Suwon, South Korea; Kyung Hee Univ, Sch Med, Dept Urol, Seoul, South Korea; Pusan Natl Univ, Yangsan Hosp, Sch Med, Dept Urol, Yangsan, South Korea; Busan Adventist Hosp, Dept Urol, Busan, South Korea; Keimyung Univ, Dongsan Hosp, Sch Med, Dept Urol, Daegu, South Korea; Ajou Univ, Sch Med, Dept Urol, Suwon, South Korea; Seoul Natl Univ, Seoul Natl Univ Hosp, Coll Med, Dept Urol, Seoul, South Korea; SMG SNU Boramae Med Ctr, Dept Urol, Seoul, South Korea; Yeungnam Univ, Coll Med, Dept Urol, Daegu, South Korea; Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Dept Urol, Seoul, South Korea; Perfect Urol Clin, Seoul, South Korea; Konkuk Univ, Med Ctr, Sch Med, Dept Urol, Seoul, South Korea; Wonkwang Univ, Wonkwang Univ Hosp, Sch Med, Inst Wonkwang Med Sci,Dept Urol, Iksan, South Korea ; Kim, Jong-Yeup/ISA-2120-2023; Lee, Jin-Ho/AEE-5544-2022; Jeon, Seung Hyun/AFN-3212-2022; Cho, Daesung/AAK-3353-2020; Oh, Kyung Jin/ABC-2135-2021; Kim, Soo-Yeon/ADR-9663-2022; Kim, Hyung Joon/F-6497-2013; Kim, Young/T-8521-2019; Yoon, Young/ABG-4983-2020; Lee, Joo Yong/ADE-2110-2022 56387960800; 55205621500; 56567178300; 55857158600; 57201976949; 55656324500; 56568723500; 55765297500; 57199747517; 57202817150; 56783481000; 57938633500; 55513422600; 12446995700; 58825663400; 57205093943; 27169373300; 57265524000; 58743468300; 58475201300; 56150089500; 58946218300; 55686246500; 37074378700; 55722526800; 55927166200; 15127262000; 58476150900; 7203005251; 6507407846; 8446634000; 57202103629 hjkim@kyuh.ac.kr; INVESTIGATIVE AND CLINICAL UROLOGY INVESTIG CLIN UROL 2466-0493 2466-054X 64 4 SCIE UROLOGY & NEPHROLOGY 2023 2.5 34.5 4.5 2025-06-25 15 16 Diagnosis; Risk management; Therapy; Urolithiasis EXTRACORPOREAL SHOCKWAVE LITHOTRIPSY; COMBINED INTRARENAL SURGERY; URETERAL WALL THICKNESS; FLEXIBLE URETEROSCOPY; RESIDUAL FRAGMENTS; WAVE LITHOTRIPSY; METABOLIC EVALUATION; MEDICAL-MANAGEMENT; STONES; PREGNANCY Diagnosis; Risk management; Therapy; Urolithiasis Humans; Republic of Korea; Urolithiasis; Urologists; allopurinol; antibiotic agent; bicarbonate; calcium; captopril; citrate potassium; febuxostat; hydrochlorothiazide; magnesium; methionine; nonsteroid antiinflammatory agent; penicillamine; pyridoxine; tasna; thiazide diuretic agent; urocitra k sr; Article; bacteriuria; calcium phosphate urolithiasis; clinical practice; computer assisted tomography; coughing; dermatitis; diabetes mellitus; diarrhea; endoscopic surgery; evidence based practice; follow up; frequently asked question; human; hypercalciuria; hyperkalemia; hyperoxaluria; hyperuricosuria; hypocitraturia; hypotension; indigestion; infection; intravenous urography; kidney function test; kidney injury; Korean Society of Endourology and Robotics; medical expulsive therapy; medical expert; medical society; metabolism; myalgia; nephrotic syndrome; pancytopenia; polyneuropathy; practice guideline; pyuria; questionnaire; skin defect; ureter stone; uric acid stone; urinary tract infection; urine pH; urolithiasis; urologist; South Korea; urolithiasis; urologist English 2023 2023-07 10.4111/icu.20230102 바로가기 바로가기 바로가기 바로가기
Article Trends of stratified prostate cancer risk in a single Korean province from 2003 to 2021: A multicenter study conducted using regional training hospital data Purpose: To identify changes in prostate cancer (PCa) risk-stratification during the last two decades in Korea, where the social per-ception of PCa was limited due to a relatively low incidence but has recently been triggered by the rapidly increasing incidence of benign prostate hyperplasia.Materials and Methods: Retrospective data of patients who had received a diagnosis of PCa in a single Korean province (Daegu-Gyeongsangbuk) at all seven training hospitals in the years 2003, 2007, 2011, 2015, 2019, and 2021 were subjected to analysis. Changes in PCa risk-stratification were investigated with respect to serum prostate-specific antigen (PSA), Gleason score (GS), and clinical stage.Results: Of the 3,393 study subjects that received a diagnosis of PCa, 64.1% had high-risk disease, 23.0% intermediate, and 12.9% low-risk disease. The proportion diagnosed with high-risk disease was 54.8% in 2003, 30.6% in 2019, but then increased to 35.1% in 2021. The proportion of patients with high PSA (>20 ng/mL) steadily decreased from 59.4% in 2003 to 29.6% in 2021, whereas the proportion with a high GS (>8) increased from 32.8% in 2011 to 34.0% in 2021, and the proportion with advanced stage dis-ease (over cT2c) increased from 26.5% in 2011 to 37.1% in 2021.Conclusions: In this retrospective study, conducted in a single Korean province, high-risk PCa accounted for the largest proportion of newly registered Korean PCa patients during the last two decades and increased in the early 2020s. This outcome supports the adoption of nationwide PSA screening, regardless of current Western guidelines. Ko, Young Hwii; Kim, Byung Hoon; Kwon, Se Yun; Jung, Hyun Jin; Hah, Yoon Soo; Kim, Yeon-Joo; Kim, Hyun Tae; Lee, Jun Nyung; Kim, Jeong Hyun; Kim, Tae-Hwan Yeungnam Univ, Dept Urol, Coll Med, Daegu, South Korea; Keimyung Univ, Dept Urol, Sch Med, Daegu, South Korea; Dongguk Univ, Dept Urol, Coll Med, Gyeongju, South Korea; Daegu Catholic Univ, Dept Urol, Sch Med, Daegu, South Korea; Daegu Fatima Hosp, Dept Urol, Daegu, South Korea; Kyungpook Natl Univ, Sch Med, Dept Urol, Daegu, South Korea; Kangwon Natl Univ, Dept Urol, Sch Med, Chunchon, South Korea Ko, Young Hwii/GRX-0718-2022; Kim, Yong-Joo/AAK-1840-2021; Kim, Hyeonjin/M-3761-2019; Kim, Tae/B-9921-2013; Kim, Byung-Hoon/AFB-5417-2022 25723368800; 57203500751; 35995613300; 7403029491; 54406906800; 57196171050; 55739531300; 16301364600; 57207436992; 57797823600 urokyh@naver.com; INVESTIGATIVE AND CLINICAL UROLOGY INVESTIG CLIN UROL 2466-0493 2466-054X 64 2 SCIE UROLOGY & NEPHROLOGY 2023 2.5 34.5 1.97 2025-06-25 7 7 Prostate-specific antigen; Prostatic neoplasms; Risk assessment PSA TESTING PATTERNS; US; MORTALITY; MEN Prostate-specific antigen; Prostatic neoplasms; Risk assessment Hospitals; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Republic of Korea; Retrospective Studies; prostate specific antigen; prostate specific antigen; adult; aged; Article; cancer diagnosis; cancer risk; cancer screening; cancer staging; computer assisted tomography; echography; Gleason score; histology; human; incidence; Korea; major clinical study; male; metastasis; multicenter study; nuclear magnetic resonance imaging; perception; prostate biopsy; prostate cancer; prostate volume; retrospective study; risk assessment; scoring system; stratification; training; trend study; clinical trial; hospital; prostate tumor; South Korea English 2023 2023-03 10.4111/icu.20220317 바로가기 바로가기 바로가기 바로가기
Article A comparison of treatment response to biologics in asthma-COPD overlap and pure asthma: Findings from the PRISM study Background: Despite the increasing use of biologics in severe asthma, there is limited research on their use in asthma-chronic obstructive pulmonary disease overlap (ACO). We compared real-world treatment responses to biologics in ACO and asthma.Methods: We conducted a multicenter, retrospective, cohort study using data from the Precision Medicine Intervention in Severe Asthma (PRISM). ACO was defined as post-bronchodilator forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) 10 pack-years. Physicians selected biologics (omalizumab, mepolizumab, reslizumab, benralizumab, and dupilumab) based on each United States Food & Drug Administration (FDA) approval criteria.Results: After six-month treatment with biologics, both patients with ACO (N = 13) and asthma (N = 81) showed positive responses in FEV1 (10.69 +/- 17.17 vs. 11.25 +/- 12.87 %, P = 0.652), Asthma Control Test score (3.33 +/- 5.47 vs. 5.39 +/- 5.42, P = 0.290), oral corticosteroid use (-117.50 +/- 94.38 vs. -115.06 +/- 456.85 mg, P = 0.688), fractional exhaled nitric oxide levels (-18.62 +/- 24.68 vs. -14.66 +/- 45.35 ppb, P = 0.415), sputum eosinophils (-3.40 +/- 10.60 vs. -14.48 +/- 24.01 %, P = 0.065), blood eosinophils (-36.47 +/- 517.02 vs. -363.22 +/- 1294.59, P = 0.013), and exacerbation frequency (-3.07 +/- 4.42 vs. -3.19 +/- 5.11, P = 0.943). The odds ratio for exacerbation and time-to-first exacerbation showed no significant difference after full adjustments, and subgroup analysis according to biologic type was also showed similar results.Conclusions: Biologics treatment response patterns in patients with ACO and asthma were comparable, suggesting that biologics should be actively considered for ACO patients as well. Shim, Ji-Su; Kim, Hyunkyoung; Kwon, Jae-Woo; Park, So-Young; Kim, Sujeong; Kim, Byung-Keun; Nam, Young-Hee; Yang, Min-Suk; Kim, Mi-Yeong; Kim, Sae-Hoon; Lee, Byung-Jae; Lee, Taehoon; Kim, Sang-Ha; Park, So Young; Cho, Young-Joo; Park, Chan Sun; Jung, Jae-Woo; Park, Han-Ki; Kim, Joo-Hee; Choi, Jeong-Hee; Moon, Ji-Yong; Adcock, Ian; Chung, Kian Fan; Kim, Min-Hye; Kim, Tae-Bum Ewha Womans Univ, Coll Med, Dept Internal Med, 260 Gonghang Daero, Seoul 07804, South Korea; Univ Ulsan, Coll Med, Asan Med Ctr, Dept Allergy & Clin Immunol, 88 Olymp Ro 43 Gil, Seoul 05505, South Korea; Kangwon Natl Univ, Sch Med, Dept Allergy & Clin Immunol, Chunchon, South Korea; Chung Ang Univ, Coll Med, Div Pulm Allergy & Crit Care Med, Dept Internal Med,Gwangmyeong Hosp, Seoul, South Korea; Kyungpook Natl Univ, Sch Med, Dept Internal Med, Daegu, South Korea; Korea Univ, Coll Med, Dept Internal Med, Seoul, South Korea; Dong A Univ, Coll Med, Dept Internal Med, Busan, South Korea; Seoul Natl Univ, Boramae Med Ctr, Dept Internal Med, Seoul Metropolitan Govt, Seoul, South Korea; Inje Univ, Coll Med, Busan Paik Hosp, Dept Internal Med, Busan, South Korea; Seoul Natl Univ, Div Allergy & Clin Immunol, Dept Internal Med, Bundang Hosp, Seongnam, South Korea; Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Med, Seoul, South Korea; Univ Ulsan, Coll Med, Ulsan Univ Hosp, Dept Internal Med, Ulsan, South Korea; Yonsei Univ, Wonju Coll Med, Dept Internal Med, Wonju, South Korea; Vet Hlth Serv Med Ctr, Dept Internal Med, Seoul, South Korea; Inje Univ, Coll Med, Haeundae Paik Hosp, Dept Internal Med, Busan, South Korea; Chung Ang Univ, Coll Med, Dept Internal Med, Seoul, South Korea; Kyungpook Natl Univ, Chilgok Hosp, Div Allergy & Clin Immunol, Dept Internal Med, Daegu, South Korea; Hallym Univ, Sacred Heart Hosp, Dept Internal Med, Anyang, South Korea; Hallym Univ, Dongtan Sacred Heart Hosp, Dept Pulmonol & Allergy, Hwaseong, South Korea; Hanyang Univ, Coll Med, Dept Internal Med, Seoul, South Korea; Imperial Coll London, Natl Heart & Lung Inst, London, England Lee, Jae-Hyun/ABE-3803-2020; Park, Han-Ki/AAY-3102-2020; Kim, Byung-Keun/N-4256-2018; Kim, Ju-Hyoung/N-1450-2019; Lee, JongGu/B-7384-2013; Jung, Jae-Woo/L-9451-2019; Kim, Hyun/AAT-6695-2021; Kim, Jin-Seok/AAK-5424-2020; Lee, Tae/B-1160-2013; MOON, Ji-yong/U-1476-2018; MOON, Ji-Yong/U-1476-2018; Chung, Kian/B-1872-2012; Kim, Sang-Ha/ACC-9085-2022; Park, Chan-Sun/AAT-3431-2021; Adcock, Ian/L-3217-2019 57193221759; 57670420000; 57204538197; 59466241200; 36666447400; 36608393400; 37006947800; 7404927140; 55892381000; 35198322400; 27171988300; 57205134034; 55718908700; 55472202600; 57191996109; 57189648165; 57218664064; 57191685789; 7501395695; 58760742600; 57201387004; 57208201733; 58045929900; 57206927697 mineyang81@ewha.ac.kr;tbkim@amc.seoul.kr; WORLD ALLERGY ORGANIZATION JOURNAL WORLD ALLERGY ORGAN 1939-4551 16 12 SCIE ALLERGY;IMMUNOLOGY 2023 3.9 34.6 0.94 2025-06-25 6 6 Asthma-COPD overlap; Asthma; Biologics; Monoclonal antibodies; Treatment response MEPOLIZUMAB; OBSTRUCTION; DEFINITION; OMALIZUMAB Asthma; Asthma-COPD overlap; Biologics; Monoclonal antibodies; Treatment response benralizumab; bronchodilating agent; corticosteroid; dupilumab; mepolizumab; omalizumab; reslizumab; adult; Article; asthma; Asthma Control Test; chronic obstructive lung disease; cohort analysis; disease course; eosinophil count; female; forced expiratory volume; forced vital capacity; fractional exhaled nitric oxide; human; major clinical study; male; middle aged; multicenter study; personalized medicine; retrospective study; smoking; sputum analysis; treatment duration; treatment response; United States English 2023 2023-12 10.1016/j.waojou.2023.100848 바로가기 바로가기 바로가기 바로가기
Article A Standardized Pathology Report for Gastric Cancer: 2nd Edition edition consists of two parts: standard data elements and conditional data elements. The standard data elements contain the basic pathologic findings and items necessary to predict the prognosis of GC patients, and they are adequate for routine surgical pathology service. Other diagnostic and prognostic factors relevant to adjuvant therapy, including molecular biomarkers, are classified as conditional data elements to allow each pathologist to selectively choose items appropriate to the environment in their institution. We trust that the standardized pathology report will be helpful for GC diagnosis and facilitate large-scale Park, Young Soo; Kook, Myeong-Cherl; Kim, Baek-hui; Lee, Hye Seung; Kang, Dong-Wook; Gu, Mi-Jin; Shin, Ok Ran; Choi, Younghee; Lee, Wonae; Kim, Hyunki; Song, In Hye; Kim, Kyoung-Mee; Kim, Hee Sung; Kang, Guhyun; Park, Do Youn; Jin, So -Young; Kim, Joon Mee; Choi, Yoon Jung; Chang, Hee Kyung; Ahn, Soomin; Chang, Mee Soo; Han, Song-Hee; Kwak, Yoonjin; Seo, An Na; Lee, Sung Hak; Cho, Mee-Yon Univ Ulsan, Asan Med Ctr, Coll Med, Dept Pathol, Seoul, South Korea; Natl Canc Ctr, Ctr Gastr Canc, Goyang, South Korea; Korea Univ, Guro Hosp, Dept Pathol, Seoul, South Korea; Seoul Natl Univ, Seoul Natl Univ Hosp, Dept Pathol, Coll Med, Seoul, South Korea; Chungnam Natl Univ, Sejong Hosp, Dept Pathol, Sch Med, Sejong, South Korea; Yeungnam Univ, Dept Pathol, Coll Med, Daegu, South Korea; Catholic Univ Korea, Dept Hosp Pathol, Uijeongbu St Marys Hosp, Coll Med, Uijongbu, South Korea; Hallym Univ, Dongtan Sacred Heart Hosp, Dept Pathol, Hwaseong, South Korea; Dankook Univ, Coll Med, Dept Pathol, Cheonan, South Korea; Yonsei Univ, Coll Med, Dept Pathol, Seoul, South Korea; Sungkyunkwan Univ, Samsung Med Ctr, Dept Pathol & Translat Genom, Sch Med, Seoul, South Korea; Chung Ang Univ, Chung Ang Univ Hosp, Dept Pathol, Coll Med, Seoul, South Korea; LabGen Clin Labs, Seongnam, South Korea; St Maria Pathol Lab, Busan, South Korea; Soonchunhyang Univ, Seoul Hosp, Dept Pathol, Seoul, South Korea; Inha Univ, Dept Pathol, Sch Med, Incheon, South Korea; Yonsei Univ, Yongin Severance Hosp, Dept Pathol, Coll Med, Yongin, South Korea; Kosin Univ, Gospel Hosp, Coll Med, Dept Pathol, Busan, South Korea; Seoul Natl Univ, Boramae Hosp, Coll Med, Dept Pathol, Seoul, South Korea; Dong A Univ, Dept Pathol, Coll Med, Busan, South Korea; Kyungpook Natl Univ, Chilgok Hosp, Sch Med, Dept Pathol, Daegu, South Korea; Catholic Univ Korea, Seoul St Marys Hosp, Dept Hosp Pathol, Coll Med, Seoul, South Korea; Yonsei Univ, Wonju Severance Christian Hosp, Dept Pathol, Wonju Coll Med, Wonju, South Korea ; Kim, Wooho/G-3703-2011; Lee, Hye Seung/LZI-3726-2025; Kook, Moochang/B-7001-2014; Kwak, Yoonjin/HOI-0139-2023; Kim, Han/C-4709-2011 55540144700; 7003734725; 16203115900; 57102095800; 55885804400; 55584780700; 8609180500; 55685949600; 55973619400; 57965263900; 57217272410; 56155892100; 58985198500; 35181393000; 57205289656; 35590135600; 57554573600; 57190118469; 12778283700; 54893655800; 7404504590; 59604183800; 56049775700; 55804153700; 57203597873; 7401727574 hakjjang@catholic.ac.kr;meeyon@yonsei.ac.kr; JOURNAL OF GASTRIC CANCER J GASTRIC CANCER 2093-582X 2093-5641 23 1 SCIE GASTROENTEROLOGY & HEPATOLOGY;ONCOLOGY 2023 3.2 34.6 2.99 2025-06-25 15 18 Korea; Association; Stomach neoplasms; Gastrectomy; Endoscopic resection; Molecular pathology LYMPH-NODE METASTASIS; ENDOSCOPIC SUBMUCOSAL DISSECTION; INDEPENDENT PROGNOSTIC-FACTOR; MISMATCH REPAIR-DEFICIENCY; EXPRESSION-BASED CLASSIFICATION; FAVORABLE RISK-FACTOR; RING CELL-CARCINOMA; MICROSATELLITE INSTABILITY; TUMOR-REGRESSION; CLINICOPATHOLOGICAL FEATURES Endoscopic resection; Gastrectomy; Molecular pathology; Pathology report; Standardization; Stomach neoplasms biological marker; DNA mismatch repair protein MSH2; epidermal growth factor receptor 2; mismatch repair protein PMS2; molecular marker; mucin; MutL protein homolog 1; pembrolizumab; protein MSH6; adenocarcinoma; adenoma; anaplastic carcinoma; Article; cancer prognosis; colloid carcinoma; depth of invasion; en bloc resection; endoscopic surgery; environment; Epstein Barr virus; gold standard; Helicobacter infection; high throughput sequencing; histology; histopathology; human; immunohistochemistry; in situ hybridization; lymph node metastasis; lymph vessel metastasis; microsatellite instability; mismatch repair; partial gastrectomy; pathologist; pathology; perineural invasion; phase 3 clinical trial (topic); polymerase chain reaction; proximal gastrectomy; radical resection; stomach adenoma; stomach cancer; stomach carcinoma; surgical margin; total gastrectomy; tumor mutational burden; tumor regression; tumor volume; ulcer; wedge resection; World Health Organization English 2023 2023-01 10.5230/jgc.2023.23.e7 바로가기 바로가기 바로가기 바로가기
Article Clinical aspects of severe cutaneous adverse reactions caused by beta-lactam antibiotics: A study from the Korea SCAR registry Background: Although beta-lactams are 1 of the major causative agents of severe cutaneous adverse reactions (SCAR), their epidemiology and clinical aspects have been poorly studied. This study aimed to investigate the characteristics of SCAR caused by beta-lactams in the Korean SCAR registry.Methods: We retrospectively analyzed beta-lactam-induced SCAR cases collected from 28 tertiary university hospitals in Korea between 2010 and 2015. The SCAR phenotypes included Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), SJS-TEN overlap, and drug reaction with eosinophilia and systemic symptoms (DRESS). Beta-lactams were classified according to their chemical structures: penicillins, cephalosporins, and carbapenems. The causative betalactams, clinical and laboratory features, treatments, and outcomes were evaluated.Results: Among the 275 antibiotic-induced SCAR cases, 170 patients developed SCAR induced by beta-lactams. Beta-lactam antibiotic-induced SCAR showed more frequent SJS/TEN compared to SCAR induced by non-beta-lactam antibiotics (SJS/TEN/SJS-TEN overlap/DRESS: 36.5/11.2/ 5.9/46.5% vs. 23.8/10.5/2.9/62.9%, P = 0.049). Cephalosporin was the most common culprit drug. Particularly, 91 and 79 patients presented with SJS/TEN and DRESS, respectively. The odds ratio (OR) for poor prognosis, such as sequelae and death, was significantly increased in subjects with SJS-TEN overlap and TEN and carbapenem as culprit drug in the multivariate analysis (OR, 35.61; P = 0.016, OR, 28.07; P = 0.006, OR 30.46; P = 0.027).Conclusion: Among antibiotic-induced SCAR, clinical features were different depending on whether the culprit drug was a beta-lactam antibiotic or SCAR type. The poor prognosis was related to SJS-TEN overlap, TEN type, and carbapenem as the culprit drug. Kim, Min-Hye; Kang, Dong Yoon; Nam, Young-Hee; Sim, Da Woon; Kim, Sujeong; Lee, Jun Kyu; Park, Jung-Won; Park, Hye-Kyung; Jung, Jae-Woo; Kim, Cheol-Woo; Yang, Min-Suk; Kim, Joo-Hee; Ye, Young-Min; Koh, Young-Il; Kang, Hye-Ryun; Park, Seoung Ju; Kim, Sae-Hoon Ewha Womans Univ, Dept Internal Med, Coll Med, Seoul, South Korea; Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea; Dong A Univ, Dept Internal Med, Coll Med, Busan, South Korea; Chonnam Natl Univ, Chonnam Natl Univ Hosp, Dept Allergy & Clin Immunol, Med Sch, Gwangju, South Korea; Kyungpook Natl Univ, Sch Med, Dept Internal Med, Daegu, South Korea; Dongguk Univ, Dept Internal Med, Ilsan Hosp, Goyang, South Korea; Yonsei Univ, Coll Med, Dept Internal Med, Seoul, South Korea; Pusan Natl Univ, Coll Med, Dept Internal Med, Busan, South Korea; Chung Ang Univ, Coll Med, Dept Internal Med, Seoul, South Korea; Inha Univ, Sch Med, Dept Internal Med, Incheon, South Korea; SMG SNU Boramae Med Ctr, Dept Internal Med, Seoul, South Korea; Hallym Univ, Dept Internal Med, Sacred Heart Hosp, Anyang, South Korea; Ajou Univ, Dept Allergy & Clin Immunol, Sch Med, Suwon, South Korea; Jeonbuk Natl Univ, Dept Internal Med, Med Sch, Jeonju, South Korea; Seoul Natl Univ, Bundang Hosp, Dept Internal Med, Seongnam, South Korea; Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul, South Korea; Ulsan Univ Hosp, Dept Prevent Med, Ulsan, South Korea ; Jung, Jae-Woo/L-9451-2019; Kim, Ju-Hyoung/N-1450-2019; Park, Hye-Kyung/Q-5586-2019; Kim, Hye/AAF-7609-2020; Kim, Dae/AAJ-7518-2021; Park, Seoungju/D-4444-2014 58045929900; 37077171700; 37006947800; 57188552688; 36666447400; 57201264381; 8591768500; 57208252986; 57189648165; 7409872246; 7404927140; 57191685789; 13405438300; 58914386100; 7404070922; 8578599900; 35198322400 sjp@jbnu.ac.kr;shkrins@snu.ac.kr; WORLD ALLERGY ORGANIZATION JOURNAL WORLD ALLERGY ORGAN 1939-4551 16 1 SCIE ALLERGY;IMMUNOLOGY 2023 3.9 34.6 0.63 2025-06-25 4 4 Antibacterial agents; Beta-lactams; Drug hypersensitivity syndrome; Stevens-Johnson syndrome; Toxic epidermal necrolysis CAUSALITY ASSESSMENT; DRUG-REACTIONS Antibacterial agents; Beta-lactams; Drug hypersensitivity syndrome; Stevens-Johnson syndrome; Toxic epidermal necrolysis beta lactam; carbapenem derivative; cephalosporin derivative; corticosteroid; immunoglobulin; penicillin derivative; adult; age distribution; Article; body mass; clinical feature; comorbidity; controlled study; demography; disease duration; disease registry; disease severity; DRESS syndrome; epidemiological data; female; hospital admission; human; major clinical study; male; mortality rate; prognostic assessment; sex difference; skin toxicity; South Korea; Stevens Johnson syndrome; Stevens Johnson/toxic epidermal necrolysis overlap syndrome; symptomatology; tertiary care center; toxic epidermal necrolysis; university hospital English 2023 2023-01 10.1016/j.waojou.2022.100738 바로가기 바로가기 바로가기 바로가기
Meeting Abstract Clinical efficacy of low-molecular-weight heparin plus aspirin versus aspirin alone in repeat pregnancy loss women with thrombotic causes Park, Joon Cheol; Kim, Dong Ja Kyungpook Natl Univ, Sch Med, Dept Obstet & Gynecol, Daegu, South Korea; Kyungpook Natl Univ, Sch Med, Dept Forens Med, Daegu, South Korea JOURNAL OF REPRODUCTIVE IMMUNOLOGY J REPROD IMMUNOL 0165-0378 1872-7603 156 SCIE IMMUNOLOGY;REPRODUCTIVE BIOLOGY 2023 2.9 34.6 0 Repeat pregnancy loss; Thrombophilia; Antiphospholipid antibodies English 2023 2023-03 10.1016/j.jri.2023.103864 바로가기 바로가기 바로가기
Article Korean Practice Guidelines for Gastric Cancer 2022: An Evidence-based, Multidisciplinary Approach Gastric cancer is one of the most common cancers in Korea and the world. Since 2004, this is the 4th gastric cancer guideline published in Korea which is the revised version of previous evidence-based approach in 2018. Current guideline is a collaborative work of the interdisciplinary working group including experts in the field of gastric surgery, gastroenterology, endoscopy, medical oncology, abdominal radiology, pathology, nuclear medicine, radiation oncology and guideline development methodology. Total of 33 key questions were updated or proposed after a collaborative review by the working group and 40 statements were developed according to the systematic review using the MEDLINE, Embase, Cochrane Library and KoreaMed database. The level of evidence and the grading of recommendations were categorized according to the Grading of Recommendations, Assessment, Development and Evaluation proposition. Evidence level, benefit, harm, and clinical applicability was considered as the significant factors for recommendation. The working group reviewed recommendations and discussed for consensus. In the earlier part, general consideration discusses screening, diagnosis and staging of endoscopy, pathology, radiology, and nuclear medicine. Flowchart is depicted with statements which is supported by meta-analysis and references. Since clinical trial and systematic review was not suitable for postoperative oncologic and nutritional follow-up, working group agreed to conduct a nationwide survey investigating the clinical practice of all tertiary or general hospitals in Korea. The purpose of this survey was to provide baseline information on follow up. Herein we present a multidisciplinary-evidence based gastric cancer guideline. Kim, Tae-Han; Kim, In-Ho; Kang, Seung Joo; Choi, Miyoung; Kim, Baek-Hui; Eom, Bang Wool; Kim, Bum Jun; Min, Byung-Hoon; Choi, Chang In; Shin, Cheol Min; Tae, Chung Hyun; Gong, Chung Sik; Kim, Dong Jin; Cho, Arthur Eung-Hyuck; Gong, Eun Jeong; Song, Geum Jong; Im, Hyeon-Su; Ahn, Hye Seong; Lim, Hyun; Kim, Hyung-Don; Kim, Jae-Joon; Yu, Jeong Il; Lee, Jeong Won; Park, Ji Yeon; Kim, Jwa Hoon; Song, Kyoung Doo; Jung, Minkyu; Jung, Mi Ran; Son, Sang-Yong; Park, Shin-Hoo; Kim, Soo Jin; Lee, Sung Hak; Kim, Tae-Yong; Bae, Woo Kyun; Koom, Woong Sub; Jee, Yeseob; Kim, Yoo Min; Kwak, Yoonjin; Park, Young Suk; Han, Hye Sook; Nam, Su Youn; Kong, Seong-Ho Gyeongsang Natl Univ, Dept Surg, Changwon Hosp, Chang Won, South Korea; Catholic Univ Korea, Seoul St Marys Hosp, Div Med Oncol, Dept Internal Med, Seoul, South Korea; Seoul Natl Univ Hosp, Dept Internal Med, Healthcare Syst Gangnam Ctr, Seoul, South Korea; Natl Evidence Based Healthcare Collaborating Agcy, Seoul, South Korea; Korea Univ, Dept Pathol, Guro Hosp, Seoul, South Korea; Natl Canc Ctr, Ctr Gastr Canc, Goyang, South Korea; Hallym Univ, Coll Med, Div Hematol Oncol, Dept Internal Med,Med Ctr, Anyang, South Korea; Samsung Med Ctr, Dept Med, Seoul, South Korea; Pusan Natl Univ Hosp, Dept Surg, Pusan, South Korea; Seoul Natl Univ, Dept Internal Med, Bundang Hosp, Seungnam, South Korea; Ewha Womans Univ, Dept Internal Med, Coll Med, Seoul, South Korea; Asan Med Ctr, Dept Surg, Div Gastrointestinal Surg, Seoul, South Korea; Univ Ulsan, Coll Med, Seoul, South Korea; Catholic Univ Korea, Eunpyeong St Marys Hosp, Dept Surg, Coll Med, Seoul, South Korea; Severance Hosp, Dept Nucl Med, Seoul, South Korea; Hallym Univ, Dept Internal Med, Coll Med, Chunchon, South Korea; Soonchunhyang Univ, Dept Surg, Cheonan, South Korea; Univ Ulsan, Ulsan Univ Hosp, Dept Hematol & Oncol, Coll Med, Ulsan, South Korea; Seoul Natl Univ, Dept Surg, Seoul Metropolitan Government, Boramae Med Ctr, Seoul, South Korea; Univ Hallym, Hallym Univ Sacred Heart Hosp, Dept Gastroenterol, Coll Med, Anyang, South Korea; Univ Ulsan, Asan Med Ctr, Dept Oncol, Coll Med, Seoul, South Korea; Pusan Natl Univ, Div Hematol Oncol, Dept Internal Med, Yangsan Hosp, Yangsan, South Korea; Sungkyunkwan Univ, Sch Med, Dept Radiat Oncol, Samsung Med Ctr, Seoul, South Korea; Catholic Kwandong Univ, Coll Med, Dept Nucl Med, Incheon, South Korea; Kyungpook Natl Univ, Chilgok Hosp, Sch Med, Dept Surg, Daegu, South Korea; Korea Univ, Coll Med, Div Oncol, Dept Internal Med,Anam Hosp, Seoul, South Korea; Sungkyunkwan Univ, Samsung Med Ctr, Dept Radiol, Seoul, South Korea; Yonsei Univ Hlth Syst, Yonsei Canc Ctr, Div Med Oncol, Seoul, South Korea; Chonnam Natl Univ, Dept Surg, Med Sch, Gwangju, South Korea; Ajou Univ, Dept Surg, Sch Med, Suwon, South Korea; Korea Univ, Dept Surg, Anam Hosp, Seoul, South Korea; Natl Canc Ctr, Dept Radiol, Goyang, South Korea; Catholic Univ Korea, Seoul St Marys Hosp, Dept Hosp Pathol, Coll Med, Seoul, South Korea; Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea; Chonnam Natl Univ, Div Hematol Oncol, Dept Internal Med, Med Sch, Hwasun, South Korea; Hwasun Hosp, Hwasun, South Korea; Yonsei Univ, Dept Radiat Oncol, Yonsei Canc Ctr, Coll Med, Seoul, South Korea; Dankook Univ Hosp, Dept Surg, Cheonan, South Korea; Severance Hosp, Dept Surg, Seoul, South Korea; Seoul Natl Univ Hosp, Dept Pathol, Seoul, South Korea; Seoul Natl Univ, Dept Surg, Bundang Hosp, Seongnam, South Korea; Chungbuk Natl Univ, Chungbuk Natl Univ Hosp, Dept Internal Med, Coll Med, Cheongju, South Korea; Kyungpook Natl Univ, Kyungpook Natl Univ Chilgok Hosp, Sch Med, Dept Internal Med, Daegu, South Korea; Seoul Natl Univ Hosp, Dept Surg, Seoul, South Korea; Seoul Natl Univ, Coll Med, Canc Res Inst, Seoul, South Korea Choi, Chang/ABH-6588-2020; Kim, Yoo-min/AAZ-6413-2020; Kim, Jwa/AAH-9915-2021; Eom, Bang/K-4412-2016; Kim, Tae/C-1272-2009; Kim, Tae/C-8884-2009; Kim, Jin Il/JWP-3629-2024; Son, Sang-Yong/U-8522-2019; Park, Joohyun/KAL-8175-2024; KANG, MIN KYU/ACI-8824-2022; Park, Ji Yeon/AAV-2471-2020; Choi, Miyoung/HZH-8501-2023; park, youngsuk/AAV-3491-2020; Yu, Jeong Il/MTC-0984-2025; Kim, Joo Hyun/C-6604-2019; Kwak, Yoonjin/HOI-0139-2023; Gong, chung sik/JCD-7106-2023; Kim, Wooho/G-3703-2011; kim, juhee/HKV-6163-2023 56706674700; 55477690000; 51261274600; 57129603200; 16203115900; 22984747200; 57191250433; 7202932034; 56555702700; 35338000300; 35211966400; 57189999095; 57204499543; 12765492600; 56107863900; 57200318052; 57205241250; 36872167500; 55616390700; 56526231200; 57201935527; 35212472500; 56675072800; 57196405216; 57189064876; 36344961500; 56423037400; 39861699600; 55584506900; 57188744111; 59537974200; 57203597873; 57201336410; 14028001300; 6506956990; 25923961900; 55043822900; 56049775700; 57223380460; 7401969147; 55617028500; 55641926600 hyesukhan@chungbuk.ac.kr;nam20131114@gmail.com;seongho.kong@snu.ac.kr; JOURNAL OF GASTRIC CANCER J GASTRIC CANCER 2093-582X 2093-5641 23 1 SCIE GASTROENTEROLOGY & HEPATOLOGY;ONCOLOGY 2023 3.2 34.6 28.44 2025-06-25 180 171 Stomach neoplasms; Chemotherapy; Endoscopy; Surgery; Guidelines ENDOSCOPIC SUBMUCOSAL DISSECTION; LONG-TERM OUTCOMES; LYMPH-NODE METASTASIS; RANDOMIZED CLINICAL-TRIAL; PYLORUS-PRESERVING GASTRECTOMY; ASSISTED DISTAL GASTRECTOMY; MULTIDETECTOR-ROW CT; PHASE-III TRIAL; ROUX-EN-Y; GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA Chemotherapy; Endoscopy; Guidelines; Stomach neoplasms; Surgery cisplatin; docetaxel; epidermal growth factor receptor; epidermal growth factor receptor 2; fluoropyrimidine; irinotecan; nivolumab; oxaliplatin; paclitaxel; pembrolizumab; trastuzumab; anemia; apoptosis; Article; B12 deficiency; body mass; body weight; cancer adjuvant therapy; cancer grading; cancer prognosis; cancer surgery; cancer therapy; cell invasion; chemoradiotherapy; chemotherapy; clinical outcome; clinical practice; colloid carcinoma; computer assisted tomography; consensus; decision making; diagnostic accuracy; disease free survival; endoscopic surgery; Epstein Barr virus; esophagectomy; esophagogastroduodenoscopy; follow up; gastrectomy; gastrojejunostomy; hepatectomy; high throughput sequencing; histology; human; immunohistochemistry; intensity modulated radiation therapy; iron deficiency anemia; lymph node dissection; malnutrition; median survival time; metastasis resection; microsatellite instability; mismatch repair; multidisciplinary team; neoadjuvant chemotherapy; neoadjuvant therapy; operation duration; outcome assessment; ovariectomy; overall survival; pathogenesis; peritoneum metastasis; practice guideline; propensity score; quality control; quality of life; receiver operating characteristic; risk factor; sensitivity and specificity; stomach cancer; survival time; systematic review; systemic therapy; thorax radiography; tumor invasion; tumor regression; tumor volume English 2023 2023-01 10.5230/jgc.2023.23.e11 바로가기 바로가기 바로가기 바로가기
Correction Korean Practice Guidelines for Gastric Cancer 2022: An Evidence-based, Multidisciplinary Approach (vol 23, pg 3, 2023) Kim, Tae-Han; Kim, In-Ho; Kang, Seung Joo; Choi, Miyoung; Kim, Baek-Hui; Eom, Bang Wool; Kim, Bum Jun; Min, Byung-Hoon; Choi, Chang In; Shin, Cheol Min; Tae, Chung Hyun; Gong, Chung Sik; Kim, Dong Jin; Cho, Arthur Eung-Hyuck; Gong, Eun Jeong; Song, Geum Jong; Im, Hyeon-Su; Ahn, Hye Seong; Lim, Hyun; Kim, Hyung-Don; Kim, Jae-Joon; Yu, Jeong Il; Lee, Jeong Won; Park, Ji Yeon; Kim, Jwa Hoon; Song, Kyoung Doo; Jung, Minkyu; Jung, Mi Ran; Son, Sang-Yong; Park, Shin-Hoo; Kim, Soo Jin; Lee, Sung Hak; Kim, Tae-Yong; Bae, Woo Kyun; Koom, Woong Sub; Jee, Yeseob; Kim, Yoo Min; Kwak, Yoonjin; Park, Young Suk; Han, Hye Sook; Nam, Su Youn; Kong, Seong-Ho Gyeongsang Natl Univ, Dept Surg, Changwon Hosp, Chang Won, South Korea; Catholic Univ Korea, Seoul St Marys Hosp, Div Med Oncol, Dept Internal Med,Coll Med, Seoul, South Korea; Seoul Natl Univ Hosp Healthcare Syst Gangnam Ctr, Dept Internal Med, Seoul, South Korea; Natl Evidence Based Healthcare Collaborating Agcy, Seoul, South Korea; Korea Univ, Dept Pathol, Guro Hosp, Seoul, South Korea; Natl Canc Ctr, Ctr Gastr Canc, Goyang, South Korea; Hallym Univ, Coll Med, Div Hematol Oncol, Dept Internal Med,Med Ctr, Anyang, South Korea; Samsung Med Ctr, Dept Med, Seoul, South Korea; Pusan Natl Univ Hosp, Dept Surg, Busan, South Korea; Seoul Natl Univ, Dept Internal Med, Bundang Hosp, Seongnam, South Korea; Ewha Womans Univ, Dept Internal Med, Coll Med, Seoul, South Korea; Asan Med Ctr, Dept Surg, Div Gastrointestinal Surg, Seoul, South Korea; Univ Ulsan, Coll Med, Seoul, South Korea; Catholic Univ Korea, Eunpyeong St Marys Hosp, Coll Med, Dept Surg, Seoul, South Korea; Severance Hosp, Dept Nucl Med, Seoul, South Korea; Hallym Univ, Coll Med, Dept Internal Med, Chunchon, South Korea; Soonchunhyang Univ, Dept Surg, Cheonan, South Korea; Univ Ulsan, Coll Med, Ulsan Univ Hosp, Dept Hematol & Oncol, Ulsan, South Korea; Seoul Natl Univ, Boramae Med Ctr, Seoul Metropolitan Govt, Dept Surg, Seoul, South Korea; Hallym Univ, Sacred Heart Hosp, Univ Hallym Coll Med, Dept Gastroenterol, Anyang, South Korea; Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea; Pusan Natl Univ, Yangsan Hosp, Dept Internal Med, Div Hematol Oncol, Yangsan, South Korea; Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Radiat Oncol, Seoul, South Korea; Catholic Kwandong Univ, Coll Med, Dept Nucl Med, Incheon, South Korea; Kyungpook Natl Univ, Chilgok Hosp, Sch Med, Dept Surg, Daegu, South Korea; Korea Univ, Coll Med, Anam Hosp, Div Oncol,Dept Internal Med, Seoul, South Korea; Sungkyunkwan Univ, Samsung Med Ctr, Dept Radiol, Seoul, South Korea; Yonsei Univ Hlth Syst, Yonsei Canc Ctr, Div Med Oncol, Seoul, South Korea; Chonnam Natl Univ, Sch Med, Dept Surg, Gwangju, South Korea; Ajou Univ, Sch Med, Dept Surg, Suwon, South Korea; Korea Univ, Anam Hosp, Dept Surg, Seoul, South Korea; Natl Canc Ctr, Dept Radiol, Goyang, South Korea; Catholic Univ Korea, Coll Med, Seoul St Marys Hosp, Dept Hosp Pathol, Seoul, South Korea; Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea; Chonnam Natl Univ, Sch Med, Dept Internal Med, Div Hematol Oncol, Hwasun, South Korea; Hwasun Hosp, Hwasun, South Korea; Yonsei Univ, Coll Med, Yonsei Canc Ctr, Dept Radiat Oncol, Seoul, South Korea; Dankook Univ Hosp, Dept Surg, Cheonan, South Korea; Severance Hosp, Dept Surg, Seoul, South Korea; Seoul Natl Univ Hosp, Dept Pathol, Seoul, South Korea; Seoul Natl Univ, Bundang Hosp, Dept Surg, Seongnam, South Korea; Chungbuk Natl Univ, Coll Med, Chungbuk Natl Univ Hosp, Dept Internal Med, Cheongju, South Korea; Kyungpook Natl Univ, Chilgok Hosp, Sch Med, Dept Internal Med, Daegu, South Korea; Seoul Natl Univ Hosp, Dept Surg, Seoul, South Korea; Seoul Natl Univ, Coll Med, Canc Res Inst, Seoul, South Korea park, youngsuk/AAV-3491-2020; Choi, Chang/ABH-6588-2020; Gong, chung sik/JCD-7106-2023; Yu, Jeong Il/MTC-0984-2025; Kim, Wooho/G-3703-2011; Kim, Jin Il/JWP-3629-2024; Kwak, Yoonjin/HOI-0139-2023; Park, Ji Yeon/AAV-2471-2020; Kim, Jwa/AAH-9915-2021; Kim, Yoo-min/AAZ-6413-2020; Kim, SooJin/LNP-4493-2024; Kim, Tae/C-1272-2009; Park, Joohyun/KAL-8175-2024; Choi, Miyoung/HZH-8501-2023; Kim, Joo Hyun/C-6604-2019; Eom, Bang/K-4412-2016; Son, Sang-Yong/U-8522-2019; Kim, Tae/C-8884-2009 56706674700; 55477690000; 51261274600; 57129603200; 16203115900; 22984747200; 57191250433; 7202932034; 56555702700; 35338000300; 35211966400; 57189999095; 57204499543; 12765492600; 56107863900; 57200318052; 57205241250; 36872167500; 55616390700; 56526231200; 57201935527; 35212472500; 56675072800; 57196405216; 57189064876; 36344961500; 56423037400; 39861699600; 55584506900; 57188744111; 59537974200; 57203597873; 57201336410; 14028001300; 6506956990; 25923961900; 55043822900; 56049775700; 57223380460; 7401969147; 55617028500; 55641926600 JOURNAL OF GASTRIC CANCER J GASTRIC CANCER 2093-582X 2093-5641 23 2 SCIE GASTROENTEROLOGY & HEPATOLOGY;ONCOLOGY 2023 3.2 34.6 15.74 2025-06-25 2 3 erratum English 2023 2023-04 10.5230/jgc.2023.23.e20 바로가기 바로가기 바로가기 바로가기
페이지 이동:

논문 데이터 용어 설명

용어 설명
WoS Web of Science. Clarivate Analytics에서 제공하는 학술 데이터베이스입니다. 해당 논문이 WoS에 수록되어 있는지 여부를 표시합니다 (○: 수록됨).
SCOPUS Elsevier에서 제공하는 세계 최대 규모의 초록 및 인용 데이터베이스입니다. 해당 논문이 SCOPUS에 수록되어 있는지 여부를 표시합니다 (○: 수록됨).
Document Type 문헌의 유형을 나타냅니다. Article(원저), Review(리뷰), Proceeding Paper(학회논문), Editorial Material(편집자료), Letter(레터) 등으로 분류됩니다.
Title 논문의 제목입니다.
Abstract 논문의 초록(요약)입니다. 연구의 목적, 방법, 결과, 결론을 간략히 요약한 내용입니다.
Authors 논문의 저자 목록입니다. 공동 저자가 여러 명인 경우 세미콜론(;)으로 구분됩니다.
Affiliation 저자들의 소속 기관 정보입니다. 대학, 연구소, 기업 등 저자가 소속된 기관명이 표시됩니다.
ResearcherID (WoS) Web of Science의 고유 연구자 식별번호입니다. 동명이인을 구분하고 연구자의 업적을 정확하게 추적할 수 있습니다.
AuthorsID (SCOPUS) SCOPUS의 고유 저자 식별번호입니다. 연구자의 모든 출판물을 추적하고 관리하는 데 사용됩니다.
Journal 논문이 게재된 학술지의 정식 명칭입니다.
JCR Abbreviation Journal Citation Reports에서 사용하는 저널의 공식 약어입니다. 저널을 간략하게 표기할 때 사용됩니다.
ISSN International Standard Serial Number. 국제표준연속간행물번호로, 인쇄본 저널에 부여되는 고유 식별번호입니다.
eISSN Electronic ISSN. 전자 버전 저널에 부여되는 고유 식별번호입니다.
Volume 저널의 권(Volume) 번호입니다. 보통 연도별로 하나의 권이 부여됩니다.
Issue 저널의 호(Issue) 번호입니다. 한 권 내에서 여러 호로 나누어 출판되는 경우가 많습니다.
WoS Edition Web of Science의 에디션입니다. SCIE(Science Citation Index Expanded), SSCI(Social Sciences Citation Index), AHCI(Arts & Humanities Citation Index) 등으로 구분됩니다.
WoS Category Web of Science의 주제 분류 카테고리입니다. 저널과 논문이 속한 학문 분야를 나타냅니다.
JCR Year 해당 저널의 JCR(Journal Citation Reports) 지표가 산출된 연도입니다.
IF (Impact Factor) 저널 영향력 지수. 최근 2년간 발표된 논문이 해당 연도에 평균적으로 인용된 횟수를 나타냅니다. 저널의 학술적 영향력을 나타내는 대표적인 지표입니다.
JCR (%) 해당 카테고리에서 저널이 위치하는 상위 백분율입니다. 값이 낮을수록 우수한 저널임을 의미합니다 (예: 5%는 상위 5%를 의미).
FWCI Field-Weighted Citation Impact. 분야별 가중 인용 영향력 지수입니다. 논문이 받은 인용을 동일 분야, 동일 연도, 동일 문헌 유형의 평균과 비교한 값입니다. 1.0이 평균이며, 1.0보다 높으면 평균 이상의 인용을 받았음을 의미합니다.
FWCI UpdateDate FWCI 값이 마지막으로 업데이트된 날짜입니다. FWCI는 인용이 누적됨에 따라 주기적으로 업데이트됩니다.
WOS Citation Web of Science에서 집계된 해당 논문의 총 인용 횟수입니다.
SCOPUS Citation SCOPUS에서 집계된 해당 논문의 총 인용 횟수입니다.
Keywords (WoS) 저자가 논문에서 직접 지정한 키워드입니다. Web of Science에 등록된 저자 키워드 목록입니다.
KeywordsPlus (WoS) Web of Science에서 자동으로 추출한 추가 키워드입니다. 논문의 참고문헌 제목에서 자주 등장하는 단어들로 생성됩니다.
Keywords (SCOPUS) 저자가 논문에서 직접 지정한 키워드입니다. SCOPUS에 등록된 저자 키워드 목록입니다.
KeywordsPlus (SCOPUS) SCOPUS에서 자동으로 추출하거나 추가한 색인 키워드입니다.
Language 논문이 작성된 언어입니다. 대부분 English이며, 그 외 다양한 언어로 작성된 논문이 포함될 수 있습니다.
Publication Year 논문이 출판된 연도입니다.
Publication Date 논문의 정확한 출판 날짜입니다 (년-월-일 형식).
DOI Digital Object Identifier. 디지털 객체 식별자로, 논문을 고유하게 식별하는 영구적인 식별번호입니다. 이를 통해 논문의 온라인 위치를 찾을 수 있습니다.